In addition, TAMs can activate insulin-like growth factor (IGF) receptors on pancreatic cancer cells by secreting IGF-1 and 2, causing pancreatic cancer to resist gemcitabine (Shiao et al., 2011). The gene discussed is IGF1; the disease is familial pancreatic carcinoma.